Intellectus Partners LLC Sells 1,708 Shares of Illumina, Inc. (NASDAQ:ILMN)

Intellectus Partners LLC cut its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 9.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,198 shares of the life sciences company’s stock after selling 1,708 shares during the quarter. Intellectus Partners LLC’s holdings in Illumina were worth $2,255,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. abrdn plc boosted its position in Illumina by 764.9% during the 4th quarter. abrdn plc now owns 339,023 shares of the life sciences company’s stock worth $47,206,000 after buying an additional 299,827 shares during the period. J.P. Morgan Private Wealth Advisors LLC acquired a new stake in Illumina during the 3rd quarter worth approximately $29,558,000. International Assets Investment Management LLC boosted its position in Illumina by 210.5% during the 4th quarter. International Assets Investment Management LLC now owns 48,194 shares of the life sciences company’s stock worth $6,711,000 after buying an additional 32,672 shares during the period. Aquila Investment Management LLC boosted its position in Illumina by 150.0% during the 4th quarter. Aquila Investment Management LLC now owns 25,000 shares of the life sciences company’s stock worth $3,481,000 after buying an additional 15,000 shares during the period. Finally, Weil Company Inc. boosted its position in Illumina by 59.2% during the 3rd quarter. Weil Company Inc. now owns 22,963 shares of the life sciences company’s stock worth $3,152,000 after buying an additional 8,539 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Illumina

In other news, CEO Jacob Thaysen bought 7,330 shares of Illumina stock in a transaction dated Thursday, February 22nd. The stock was purchased at an average price of $135.29 per share, for a total transaction of $991,675.70. Following the purchase, the chief executive officer now directly owns 14,861 shares in the company, valued at approximately $2,010,544.69. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.17% of the stock is currently owned by company insiders.

Illumina Price Performance

ILMN stock traded up $1.23 during midday trading on Friday, reaching $122.28. 829,331 shares of the company’s stock traded hands, compared to its average volume of 1,470,247. The firm’s fifty day moving average price is $131.51 and its 200-day moving average price is $127.31. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.29 and a current ratio of 1.66. Illumina, Inc. has a 52 week low of $89.00 and a 52 week high of $213.91.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 8th. The life sciences company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.13. The business had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.09 billion. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. Illumina’s quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.14 EPS. On average, sell-side analysts predict that Illumina, Inc. will post 0.91 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on ILMN shares. Stephens reiterated an “overweight” rating and set a $170.00 target price on shares of Illumina in a research report on Wednesday, April 10th. OTR Global restated a “mixed” rating on shares of Illumina in a research report on Wednesday, March 20th. HSBC downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. StockNews.com upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research report on Friday, February 16th. Finally, Barclays boosted their price target on shares of Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a research report on Wednesday, April 10th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, Illumina presently has an average rating of “Hold” and a consensus target price of $167.70.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.